Abstract Introduction: The American Thyroid Association appointed a Task Force of experts
to revise the original Medullary Thyroid Carcinoma: Management Guidelines of the …

Introduction Over the past years, the incidence of thyroid cancer has surged not only in
Germany but also in other countries of the Western hemisphere. This surge was first and …

Background Oncogenic alterations in RET represent important therapeutic targets in thyroid
cancer. We aimed to assess the safety and antitumour activity of pralsetinib, a highly potent …

Purpose Cabozantinib, a tyrosine kinase inhibitor (TKI) of hepatocyte growth factor receptor
(MET), vascular endothelial growth factor receptor 2, and rearranged during transfection …

Background Primary analysis of the double-blind, phase III Efficacy of XL184 (Cabozantinib)
in Advanced Medullary Thyroid Cancer (EXAM) trial demonstrated significant improvement …

Purpose XL184 (cabozantinib) is a potent inhibitor of MET, vascular endothelial growth
factor receptor 2 (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti …

Background: Medullary thyroid carcinoma (MTC) is a well-differentiated thyroid tumor that
maintains the typical features of C cells. An advanced stage and the presence of lymph node …

The variety of diseases caused by mutations in RET receptor tyrosine kinase provides a
classic example of phenotypic heterogeneity. Gain-of-function mutations of RET are …

RET/papillary thyroid carcinoma (PTC) oncogenes, generated by recombination of the
tyrosine kinase-encoding domain of RET with different heterologous genes, are prevalent in …

Purpose Mutations in the RET proto-oncogene and vascular endothelial growth factor
receptor (VEGFR) activity are critical in the pathogenesis of medullary thyroid cancer (MTC) …